5q- syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide.

Abstract

A 72-year-old woman was diagnosed with 5q- myelodysplastic syndrome in the course of an indolent multiple myeloma (MM). Bone marrow (BM) cytogenetics disclosed two unrelated clones: 46,XX,del(5)(q13q33), and [47,X,-X,der(1;21)(q10;q10),-4,-4,+5,del(5)(q13q31),+7,der(7)t(1;7)(p34.2;p22),add(8)(p23),-13,+15,der(16) t(1;16)(q23;q12.2),+19,-21,+mar1,+mar2]. The last complex karyotype belonged to malignant plasma cells. FISH and SKY techniques demonstrated different 5q deletions. EGR1 gene (on 5q31) lost in 5q- syndrome remained in 5q- plasma cells. Biclonal evolution was noted: myeloid 5q- cells added a deletion 13q and plasma cells showed monosomy 13. Patient achieved complete cytogenetic response of 5q- syndrome with low-dose of lenalidomide, and a partial remission of MM with high-dose of lenalidomide/dexamethasone combination.

• Authors: Margarita Ortega, Mar Mallo, Francesc Solé, Carmen Sánchez-Morata, Laura López-Andreoni, Noemí Martínez-Morgado, Mercedes Gironella, David Valcárcel, Teresa Vallespí
• Journal: Leukemia research (Leuk Res) Vol. 37 Issue 10 Pg. 1248-50 (Oct 2013) ISSN: 1873-5835 [Electronic] England
• PMID: 23891188 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2013 Elsevier Ltd. All rights reserved.

Chemical References

• Thalidomide
• Lenalidomide

Topics

• Abnormal Karyotype
• Aged
• Anemia, Macrocytic (complications, diagnosis, drug therapy)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Chromosome Banding
• Chromosome Deletion
• Chromosomes, Human, Pair 5
• Female
• Humans
• Lenalidomide
• Multiple Myeloma (complications, diagnosis, drug therapy)
• Thalidomide (administration & dosage, analogs & derivatives, therapeutic use)
• Treatment Outcome